论文部分内容阅读
目的探讨不同药物联合应用米非司酮在终止瘢痕子宫中期妊娠中的疗效对比。方法本次实验以我院2010年1月至2011年1月所收治的70例瘢痕子宫中期妊娠患者为实验对象,将患者随机分为依沙吖啶组和米索前列醇组,依沙吖啶组患者使用依沙吖啶和米非司酮进行联合治疗,米索前列醇组使用米索前列醇和米非司酮进行联合治疗,对比分析两组患者的临床治疗效果。结果经过治疗,依沙吖啶组患者在治疗的总有效率、胎盘胎膜残留、出血量、总产程和宫缩发动时间等方面都显著优于米索前列醇组患者。结论本次临床实验的结果表明,依沙吖啶联合米非司酮用于终止瘢痕子宫中期妊娠,具有较为显著的临床治疗效果,因而临床推广价值更高。
Objective To investigate the curative effect of different drugs in combination with mifepristone in terminating scar pregnancy. Methods In this study, 70 pregnant women with uterus of uterus in our hospital from January 2010 to January 2011 were enrolled in this study. The patients were randomly divided into ethacridine group and misoprostol group, Patients in the nimodipine group were treated with ethacridine and mifepristone. Patients in the misoprostol group were treated with misoprostol and mifepristone, and the clinical effects were compared between the two groups. Results After treatment, patients in the Ethacridine group were significantly better than those in the misoprostol group in terms of the total effective rate of treatment, residual fetal placenta, amount of bleeding, total labor and duration of contractions. Conclusion The results of this clinical trial showed that the combination of Ethacridine and mifepristone for termination of uterine scar pregnancy has a significant clinical effect and therefore has a higher clinical value.